

PROBIOTICS RESOURCE CENTER

Theater Schedule

Speakers Bio & Abstract

DAY 2

Thursday November 3, 2022

11:20 - 12:00

Dr. Kishan PV

Head of Medical Affairs at Sanzyme Biologics

Bio

Kishan has over 17 years of experience in research and development activities around human health and wellness. He leads clinical research, innovation, and product development activities in his current role at Sanzyme Biologics.

His current focus is to develop and test effective probiotic solutions for handling gut dysbiosis and managing gut microbiome disorders. Kishan has expertise in handling full scope BE, Phase 1 through 4 clinical trials, and post-marketing surveillance studies, etc. He carries vast experience in probiotics, hormones, biosimilars, and vaccine clinical trials. He earned his Doctorate of Medicine (DM) in Clinical Pharmacology & Therapeutics from Nizam Institute of Medical Sciences, Hyderabad, India.



Company

Sanzyme Biologics® (founded as Uni-Sankyo in the year 1969) is a pioneer in probiotics. Today, it has a market presence in over 40 countries across the globe, including the US, Canada, Europe, Japan, South Korea, Australia, New Zealand, India, China, and Taiwan.

Sanzyme Biologics manufactures aerobic spore formers (*Bacillus coagulans* SNZ 1969®, *Bacillus clausii* SNZ 1971™, and *Bacillus subtilis* SNZ 1972™), aerobic vegetative strains (*Lactobacillus* spp. etc.) and yeast (*Saccharomyces boulardii* SNZ 1986™) in its world class NSF certified facility at Hyderabad, India. It adopts proprietary technology and has a sound selection of strains meeting global standards.

Flagship strain *Bacillus coagulans* SNZ 1969® spores are robust and offers flexibility to food, supplement, and pharma product formulators. It sustains processing conditions, gut pH, bile salt and does not require cold chain unlike vegetative probiotic strains. It has US FDA GRAS (including infants), Health Canada approval, non-GMO project verified and supported with 30 plus scientific publications around gut health, oral health, and women's health. SNZ 1969® could be incorporated in a wide variety of food and beverage formats such as cereal bars, protein bars, meal replacers, breakfast cereals, tea, coffee, kombucha, cookies, seasonings, nuts, chocolates, lozenges, mint tablets, gummies, hard boiled candies, HFDs, fat spreads etc.

സന്യൈം ബയോളജിക്സ്
Sanzyme Biologics

***Bacillus coagulans* SNZ 1969® supplementation for irritable bowel syndrome**

Abstract

Probiotic potential of various *Bacillus coagulans* strains has been studied in patients with constipation predominant irritable bowel syndrome (IBS-C) and diarrhea predominant irritable bowel syndrome (IBS-D). We assessed efficacy and safety of *Bacillus coagulans* SNZ 1969 in patients with IBS-C and IBS-D. *Bacillus coagulans* SNZ 1969 is found to be safe and effective alternative therapeutic option for IBS patients, thus alleviating IBS-associated clinical symptoms and improving the quality of life of IBS patients as compared to placebo.

Key Elements

- *Bacillus coagulans* SNZ 1969 is found to be safe and effective alternative therapeutic option for constipation predominant (IBS-C) and diarrhea predominant (IBS-D) patients.
- Single strain probiotic with a higher dose (daily dose of probiotics $\geq 100B$ CFU) and shorter duration (< 8 weeks) seem to be a better choice of probiotic for IBS patients.
- In terms of efficacy, *Bacillus coagulans* SNZ 1969 has shown significant improvement in global IBS symptoms, individual IBS symptom scores (such as abdominal pain and bloating) and QoL of IBS patients.